Podratz K C, Schray M F, Wieand H S, Edmonson J H, Jefferies J A, Long H J, Malkasian G D, Stanhope C R, Wilson T O
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905.
Gynecol Oncol. 1988 Sep;31(1):9-24. doi: 10.1016/0090-8258(88)90262-4.
During the 9-year interval 1977 through 1985, of 250 patients undergoing second-look laparotomy, 116 (46%) were found to have clinically occult ovarian carcinoma. Salvage therapy consisted of external irradiation in 37, intraperitoneal 32P in 12, chemotherapy in 63, and no therapy in 3 or other therapy in 1. Eligible follow-up time ranged from 1 to 9 years. The Kaplan-Meier projected median time-to-progression and survival were 15 and 22.5 months, respectively, with 4-year progression-free and overall survival rates being 21 and 27%, respectively. Survival was independent of the original stage of disease but was significantly influenced by histologic grade and microscopic (55%) versus macroscopic (19%) residual tumor after the laparotomy. Projected 4-year salvage rates in patients with microscopic or residual disease less than or equal to 5 mm was 72, 39, and 19% for intraperitoneal 32P, external irradiation (33/37, whole abdominopelvic), and chemotherapy, respectively. However, multivariable analysis demonstrated that histologic grade and isotope therapy retained independent influence on survival, but no therapeutic advantage for external irradiation over chemotherapy was demonstrable. Furthermore, use of regimens that were identical to, partially altered from, or different from the first-trial agents did not affect chemotherapy salvage rates.
在1977年至1985年的9年期间,250例行二次剖腹探查术的患者中,有116例(46%)被发现患有临床隐匿性卵巢癌。挽救性治疗包括37例接受体外照射、12例接受腹腔内32P治疗、63例接受化疗、3例未接受治疗或1例接受其他治疗。符合条件的随访时间为1至9年。根据Kaplan-Meier法预测,疾病进展的中位时间和生存期分别为15个月和22.5个月,4年无进展生存率和总生存率分别为21%和27%。生存情况与疾病的初始分期无关,但受组织学分级以及剖腹探查术后显微镜下(55%)与肉眼可见(19%)残留肿瘤的显著影响。对于显微镜下或残留病灶小于或等于5mm的患者,腹腔内32P、体外照射(33/37,全腹盆腔照射)和化疗的预测4年挽救率分别为72%、39%和19%。然而,多变量分析表明,组织学分级和同位素治疗对生存仍有独立影响,但未显示出体外照射相对于化疗的治疗优势。此外,使用与初次治疗药物相同、部分改变或不同的治疗方案对化疗挽救率没有影响。